Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference52 articles.
1. NICE. Final appraisal document (FAD). Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. 2022; https://www.nice.org.uk/guidance/ta818/documents/html-content-4.
2. NICE. Committee papers 2021. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]. 2021; https://www.nice.org.uk/guidance/ta818/evidence.
3. Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25(142):472–86.
4. Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, et al. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446–51.
5. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–86.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献